Table 2

Differences in heart rate and heart rate variability between protease inhibitor-based regimens and NNRTI-based regimens

Model 1: unadjustedModel 2: adjusted for age, gender, race and NRTI backboneModel 3: adjusted for model 2 plus smoking status, total cholesterol/HDL ratio, BMI, history of CVD events* at baseline, diabetes, blood pressure-lowering drugs and lipid-lowering drugsModel 4: adjusted for model 3 plus baseline time since first prescribed ART, baseline CD4 and HIV-RNA
MeasureDifference (95% CI)p Value*Difference (95% CI)p Value*Difference (95% CI)p Value*Difference (95% CI)p Value*
Heart Rate (bpm)
 Boosted PI−1.52 (−2.46 to −0.57)0.002−1.67 (−2.65 to −0.69)<0.001−1.93 (−2.91 to −0.96)<0.001−2.15 (−3.14 to −1.16)<0.001
 Non-boosted PI−1.84 (−2.92 to −0.75)<0.001−2.08 (−3.18 to −0.98)<0.001−2.62 (−3.70 to −1.53)<0.001−2.81 (−3.90 to −1.71)<0.001
 NNRTI-no PIRef.Ref.Ref.Ref.
SDNN (log 10 ms)
 Boosted PI0.01 (−0.01 to 0.04)0.350.01 (−0.01 to 0.04)0.380.02 (−0.01 to 0.04)0.190.02 (−0.01 to 0.05)0.12
 Non-boosted PI0.02 (−0.01 to 0.05)0.220.03 (0.00 to 0.06)0.030.04 (0.01 to 0.07)0.0060.04 (0.01 to 0.07)0.004
 NNRTI-no PIRef.Ref.Ref.Ref.
rMSSD (log 10 ms)
 Boosted PI0.02 (−0.01 to 0.04)0.220.01 (−0.01, 0.04)0.270.02 (−0.00 to 0.05)0.090.03 (0.00 to 0.05)0.04
 Non-boosted PI0.02 (−0.01 to 0.05)0.140.03 (0.00 to 0.06)0.040.04 (0.01 to 0.07)0.0030.05 (0.02 to 0.08)0.001
 NNRT-no PIRef.Ref.Ref.Ref.
  • *p Value <0.01 is considered significant.

  • bpm, beats/min; ms, millisecond; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; rMSSD, the root mean square of successive differences in the RR intervals; SDNN, the SD of all filtered RR intervals over the length of the recording.